NexCure
nexcure.com
AI Consulting & Integration
Oncology Therapeutics
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$38M
2 rounds on record
Latest round
$19M
Series A · Oct 2026 · this month
Team
51-200
employees, estimated range
Backers
1
RA Capital Management
The money's age
Fresh money
0 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Oct 2026 | $19M | — | pharmexec.com |
| Seed | Mar 2026 | $19M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
KAHR Bio: Pioneering Immunotherapeutics for Advanced Cancer Treatment.
Enara Bio is a science-led immunotherapy company developing novel T-cell directed cancer therapies. Its EDAPT platform discovers Dark…
Eisbach Bio is a clinical-stage biotechnology company developing next-generation cancer therapies with its proprietary ALLOS platform.
Accent is pioneering a new class of small molecule precision cancer therapies that target critical intracellular dependencies that span…
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
Innovating Beyond. We are dedicated to advancing transformative medicines for people living with serious respiratory diseases, leveraging…
Overview
NexCure expands access to advanced cancer therapies through outpatient clinics, delivering compassionate, innovative care with AI integration for better outcomes.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Pharma Funding Roundup: Cognito Therapeutics Closes Oversubscribed $105 Million Series C Financing, Nexcure Launches $19 Million Series A Financing PharmExec
Cognito Therapeutics and NexCure have each closed new funding rounds this week, advancing an at-home Alzheimer
Read more
Report
Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds PharmExec
In today's Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intelligence and large language models reshape pharmacovigilance and drug safety monitoring, and Eli Lilly launc
Read more
Report
NexCure获得1900万美元种子轮融资_腾讯新闻
NexCure是一家医疗服务平台运营商在社区和门诊环境中提供临床密集型治疗重新设计CAR-T及其他先进治疗的提供、监测和扩展方式NexCure将医院级临床严谨性转化为可扩展的社区门诊诊所专为下一代治疗设计其平台集成了AI驱动的患者选择、远程监测和标准化临床方案确保每位患者都能获得安全、富有同情心且个性化的治...
Read more
Report
Report
NexCure: $19 Million Raised To Expand Community-Based Access To CAR-T And Advanced Therapies
NexCure, a healthcare company focused on expanding access to complex treatments, has launched with $19 million in series a financing to support the delivery of CAR-T and other advanced therapies in community outpatient settings. The funding round was led
Read more
Report
NexCure, Inc. Launches with $19 Million Series A Financing to enable CAR-T and other advanced treatment delivery in community outpatient settings
NexCure, Inc. today launched with a bold mission to address one of healthcare
Read more
Report
NexCure, Inc. Launches with $19 Million Series A Financing to enable CAR-T and other advanced treatment delivery in community outpatient settings
/PRNewswire/ -- NexCure, Inc. today launched with a bold mission to address one of healthcare
Read more
Report